Key result
This review discusses the assessment and pharmacologic management of neonatal hypertension, including the use of beta blockers, ACE inhibitors, calcium channel blockers, and diuretics.
This review outlines the assessment and pharmacologic management of neonatal hypertension, an uncommon but significant condition.
May guide assessment of rare neonatal hypertension; leaves open optimal agent selection pending controlled trials.
Neonatal hypertension, defined as systolic blood pressure greater than 95th percentile for age, size, and gender, is an uncommon but significant problem. Hypertension may develop secondary to thromboembolic complications of central lines, steroid use, or be a sign of an underlying renal or cardiac problem. Pharmacologic management of hypertension in the neonate includes use of beta blockers, angiotensin-converting enzyme inhibitors, calcium channel blockers, and/or diuretics. This article discusses issues in assessment and management of neonatal hypertension and reviews the pharmacologic agents most commonly utilized in the neonatal setting.
No takes yet. Share an insight, caveat, or question.
Karen Kilian (2003) conducted a review in Neonatal hypertension. Pharmacologic management (beta blockers, ACE inhibitors, calcium channel blockers, diuretics) was evaluated. This review discusses the assessment and pharmacologic management of neonatal hypertension, including the use of beta blockers, ACE inhibitors, calcium channel blockers, and diuretics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: